Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole
NCT ID: NCT06937476
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
108 participants
INTERVENTIONAL
2025-05-08
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Previous clinical observations and experimental studies suggest that aripiprazole, a partial dopamine D2 receptor agonist, can significantly improve cognitive symptoms and reduce rumination in MDD patients when added to selective serotonin reuptake inhibitors (SSRIs). However, rigorous randomized controlled trials (RCTs) directly targeting rumination and validating this effect remain limited.
In this study, patients with acute MDD episodes and high levels of rumination will be randomly assigned to receive either escitalopram monotherapy (20 mg/day) or escitalopram (20 mg/day) plus low-dose aripiprazole (2.5-5 mg/day) for 8 weeks. The assignment will remain blinded to outcome assessors and data analysts, while patients and treating clinicians will remain unblinded due to dose titration and safety monitoring requirements.
Participants will undergo \[18F\]fallypride-PET-MRI scanning at baseline and post-treatment to measure striatal dopamine D2 receptor binding and explore its association with changes in rumination symptoms and treatment efficacy.
The primary outcome is the change in Ruminative Responses Scale (RRS) scores. Secondary outcomes include changes in depressive symptoms and dopamine D2 receptor availability. This trial will provide neurobiological insights into the dopaminergic mechanisms underlying pathological rumination and explore the therapeutic potential of D2 receptor modulation in this cognitive domain.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
NCT00953745
Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
NCT01696617
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
NCT00608543
Repetitive Behavior Disorders in People With Severe Mental Retardation
NCT00491478
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
NCT00882362
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Pathological rumination is characterized by repetitive, intrusive, and difficult-to-control negative thinking that often persists even after depressive symptoms remit. It has been recognized as a proximal risk factor for the onset, maintenance, and recurrence of major depressive disorder (MDD). Recent meta-analyses and longitudinal studies have confirmed that rumination significantly contributes to poor treatment outcomes and is associated with trait-like persistence across diagnostic and symptomatic states.
Rationale:
Aripiprazole, a partial dopamine D2 receptor agonist, has shown potential in augmenting antidepressant therapy by improving cognitive control and reducing rumination. Clinical observations have suggested that adjunctive aripiprazole can significantly alleviate ruminative symptoms in MDD patients, yet high-quality randomized controlled trials (RCTs) directly targeting rumination as a primary outcome remain lacking. Dopaminergic dysfunction-particularly altered D2 receptor availability in the striatum-may underlie the neurobiological mechanisms of pathological rumination. Therefore, combining pharmacological intervention with molecular neuroimaging offers a promising translational approach to validate therapeutic targets.
Study Design:
This study adopts a randomized, single-blind (assessor-blind) controlled trial design. Eligible participants include unmedicated or drug-naive MDD patients with high levels of rumination and healthy controls. Patients with pathological rumination will be randomly assigned to one of two intervention arms:
Group I: Escitalopram (20 mg/day) + aripiprazole (2.5-5 mg/day) Group II: Escitalopram monotherapy (20 mg/day)
The aripiprazole dose will be titrated from 2.5 mg/day to a maximum of 5 mg/day based on tolerability. During weeks 9-10, aripiprazole will be tapered and discontinued, with escitalopram maintained. No additional psychotropic medications are allowed. Outcome assessors and data analysts will remain blinded to treatment allocation to minimize assessment bias.
Neuroimaging Assessment:
Participants will undergo two \[18F\]fallypride-PET-MRI scans (at baseline and at the end of treatment in week 8). The scanning protocol includes:
Intravenous injection of 5 mCi \[18F\]-fallypride Dynamic PET acquisition in three blocks (70 min, 50 min, 60 min) with resting intervals Image reconstruction of binding potential (BPND) maps using simplified reference tissue modeling (SRTM), with the cerebellum as the reference region
Outcome Measures:
Primary outcome: Change in Ruminative Responses Scale (RRS) score Secondary outcomes: Changes in depressive symptoms (e.g., HAMD), striatal D2 receptor BPND values, and the correlations between imaging changes and clinical improvement
Hypothesis:
Aberrant striatal dopamine D2 receptor availability is a neurobiological substrate of pathological rumination. Modulating D2 receptor activity via aripiprazole can reduce rumination and enhance treatment response. Neuroimaging markers are expected to correlate with symptom improvement, providing mechanistic insight into the dopaminergic contributions to depressive cognition.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Escitalopram Only - MDD with Pathological Rumination
Patients diagnosed with major depressive disorder (MDD) and exhibiting pathological rumination will receive escitalopram monotherapy at 20 mg/day for 8 weeks.
Escitalopram
Escitalopram will be administered orally at a fixed dose of 20 mg/day for 8 weeks. This SSRI antidepressant is used as baseline pharmacological treatment for patients with major depressive disorder (MDD), either as monotherapy or in combination with aripiprazole. No other psychotropic medications are allowed during the study period.
Escitalopram + Aripiprazole - MDD with Pathological Rumination
Patients with MDD and pathological rumination will receive escitalopram (20 mg/day) and low-dose aripiprazole (2.5-5 mg/day) for 8 weeks, with titration based on tolerability.
Escitalopram
Escitalopram will be administered orally at a fixed dose of 20 mg/day for 8 weeks. This SSRI antidepressant is used as baseline pharmacological treatment for patients with major depressive disorder (MDD), either as monotherapy or in combination with aripiprazole. No other psychotropic medications are allowed during the study period.
Aripiprazole 5mg
Aripiprazole will be administered as an adjunctive treatment to escitalopram at an initial dose of 2.5 mg/day, titrated up to 5 mg/day based on tolerability. Treatment will last 8 weeks, after which aripiprazole will be tapered and discontinued. This intervention aims to evaluate the efficacy of dopaminergic augmentation in reducing pathological rumination symptoms.
MDD with Low Rumination - Observational
MDD patients with low levels of rumination (RRS \< 61) will receive no pharmacological intervention and serve as a naturalistic observation group.
No interventions assigned to this group
Healthy Controls
Healthy individuals with no psychiatric history will serve as non-clinical imaging and behavioral controls.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Escitalopram
Escitalopram will be administered orally at a fixed dose of 20 mg/day for 8 weeks. This SSRI antidepressant is used as baseline pharmacological treatment for patients with major depressive disorder (MDD), either as monotherapy or in combination with aripiprazole. No other psychotropic medications are allowed during the study period.
Aripiprazole 5mg
Aripiprazole will be administered as an adjunctive treatment to escitalopram at an initial dose of 2.5 mg/day, titrated up to 5 mg/day based on tolerability. Treatment will last 8 weeks, after which aripiprazole will be tapered and discontinued. This intervention aims to evaluate the efficacy of dopaminergic augmentation in reducing pathological rumination symptoms.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Age 18 to 45 years old, any sex.
Han Chinese, right-handed.
Education level of junior high school or above, able to understand informed consent and complete self-report instruments.
Meets DSM-5 diagnostic criteria for Major Depressive Disorder (MDD) based on the SCID interview.
Currently experiencing a depressive episode:
HAMD-24 score ≥ 21
YMRS score ≤ 5
No psychotropic medication (except benzodiazepines) in the past 6 weeks.
Classified into one of two cognitive subgroups based on rumination:
Pathological Rumination Group: Must meet all three of the following:
1. Subjective experience (e.g., "I can't stop thinking about past regrets" or "I can't control painful thoughts...")
2. Interview-confirmed features of pathological rumination (all of the following):
Repetitive Intrusive Difficult to disengage Unproductive Capturing mental capacity
3. Ruminative Responses Scale (RRS) score ≥ 61
Low Rumination Group: Does not meet the above criteria.
Exclusion Criteria
MDD with psychotic features.
Severe suicidal ideation or behavior.
History of traumatic brain injury or loss of consciousness.
Serious neurological or medical illness (e.g., thyroid disorders, lupus, diabetes, infection, trauma).
Cardiac pacemaker or any metallic implants incompatible with MRI/PET.
History of alcohol or substance dependence.
Pregnant or breastfeeding.
Personal or family history of epilepsy.
Underwent non-pharmacological psychiatric interventions (e.g., ECT, rTMS, psychotherapy) in the past 6 months.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Xiangya Hospital of Central South University
OTHER
National Natural Science Foundation of China
OTHER_GOV
Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhang Yan
Principal Investigator, Department of Psychiatry, The Second Xiangya Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Zhang
Role: PRINCIPAL_INVESTIGATOR
Second Xiangya Hospital of Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
van der Velden AM, Scholl J, Elmholdt EM, Fjorback LO, Harmer CJ, Lazar SW, O'Toole MS, Smallwood J, Roepstorff A, Kuyken W. Mindfulness Training Changes Brain Dynamics During Depressive Rumination: A Randomized Controlled Trial. Biol Psychiatry. 2023 Feb 1;93(3):233-242. doi: 10.1016/j.biopsych.2022.06.038. Epub 2022 Jul 22.
Song AK, Hay KR, Trujillo P, Aumann M, Stark AJ, Yan Y, Kang H, Donahue MJ, Zald DH, Claassen DO. Amphetamine-induced dopamine release and impulsivity in Parkinson's disease. Brain. 2022 Oct 21;145(10):3488-3499. doi: 10.1093/brain/awab487.
Wang Y, Lu Z, Xun G. Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial. J Affect Disord. 2024 Jan 1;344:159-168. doi: 10.1016/j.jad.2023.10.038. Epub 2023 Oct 10.
Ehring T. Thinking too much: rumination and psychopathology. World Psychiatry. 2021 Oct;20(3):441-442. doi: 10.1002/wps.20910. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LYG20230074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.